Cy5.5 NHS Ester (Non-Sulfonated): Empowering Near-Infrared Fluorescent Labeling in Molecular Biology and In Vivo Imaging

Principle and Setup: Harnessing a High-Performance Near-Infrared Fluorescent Dye for Biomolecule Labeling

Cy5.5 NHS ester (non-sulfonated), available from APExBIO, is a next-generation near-infrared fluorescent dye for biomolecule labeling. Its chemical reactivity and spectral properties are tailored for covalent labeling of primary amine-containing molecules, including proteins, peptides, and oligonucleotides. The dye features an NHS ester group that forms stable amide bonds with amino groups, enabling precise and robust conjugation workflows.

Key physicochemical characteristics underpinning its performance include:

• Excitation/Emission: Maximal excitation at 684 nm and emission at 710 nm (cy5 5 excitation emission), minimizing background autofluorescence and maximizing signal-to-noise in deep-tissue and in vivo imaging.
• High Extinction Coefficient: 209,000 M⁻¹cm⁻¹ for exceptional brightness and detection sensitivity.
• Quantum Yield: 0.2, balancing brightness with photostability for prolonged imaging sessions.
• Solubility: ≥ 35.82 mg/mL in DMSO, supporting the preparation of concentrated stock solutions for efficient labeling reactions (fluorescent dye solubility in DMSO).
• Storage: Solid form stable up to 24 months at -20°C in the dark; solutions should be freshly prepared and protected from light (storage of fluorescent dyes).

These features make Cy5.5 NHS ester (non-sulfonated) the label of choice for applications where deep-tissue penetration, minimal background, and covalent linkage are critical, such as optical imaging of tumors, in vivo fluorescence imaging, and advanced fluorescent labeling in molecular biology.

Step-by-Step Workflow: Enhanced Protocols for Protein, Peptide, and Oligonucleotide Labeling

Successful deployment of this amino group labeling reagent relies on a workflow optimized for the dye’s unique solubility and reactivity. Below is a protocol framework, adaptable for protein and peptide labeling, oligonucleotide labeling, and plasmid DNA labeling workflows.

1. Preparation of Dye Stock Solution

• Dissolve Cy5.5 NHS ester (non-sulfonated) in anhydrous DMSO or DMF at 5–10 mM (e.g., 7.16 mg in 1 mL DMSO for a 10 mM stock). Ensure minimal exposure to light.
• Vortex gently to ensure full dissolution. Do not store the solution for extended periods; use immediately after preparation.

2. Buffer Preparation and Biomolecule Handling

• Buffer (typically PBS or carbonate buffer, pH 7.4–8.5) should be free of primary amine contaminants (avoid Tris or glycine).
• Desalt or dialyze proteins/oligonucleotides into amine-free buffer prior to labeling.

3. Conjugation Reaction

• Add dye stock to the biomolecule solution at a recommended molar ratio (e.g., 3–10:1 dye:protein for proteins; optimize for labeling density).
• Incubate at room temperature (20–25°C) for 1 hour, shielded from light. For oligonucleotides, a slightly higher pH (8.5) can enhance reactivity.

4. Quenching and Purification

• Quench unreacted NHS ester by adding ethanolamine to a final concentration of 10–50 mM and incubate for 15 minutes.
• Purify labeled biomolecule by size-exclusion chromatography (e.g., Sephadex G-25) or dialysis to remove free dye.
• Confirm labeling by absorbance at 684 nm (excitation emission cy5), and calculate dye/protein or dye/oligo ratio using extinction coefficients.

This protocol ensures reliable covalent attachment, supporting fluorescent labeling for flow cytometry, western blot, and cell imaging workflows with high reproducibility.

Advanced Applications and Comparative Advantages

Cy5.5 NHS ester (non-sulfonated) is engineered for advanced imaging and molecular labeling needs, offering clear advantages for:

• In Vivo Tumor Imaging: With its near-infrared excitation and emission, this tumor imaging agent enables high-contrast, deep-tissue visualization of tumor margins in live animal models and translational studies.
• Optical Imaging of Subcutaneous Tumors and Xenografts: The dye’s low background autofluorescence and strong signal make it ideal for tumor xenograft imaging and monitoring therapeutic response in real time.
• Neuromodulation and Biomedical Research: As evidenced in recent research on piezo-nanoplatforms for non-invasive epilepsy treatment, near-infrared fluorescent probes such as Cy5.5 NHS ester (non-sulfonated) facilitate non-invasive tracking and functional studies of nanoscale therapeutic systems in vivo.
• Protein, Peptide, and Oligonucleotide Labeling: The dye’s robust NHS chemistry and high extinction coefficient support sensitive detection and quantification, even at low biomolecule concentrations.

In a comparative analysis, Cy5.5 NHS ester (non-sulfonated) consistently outperforms legacy fluorophores in deep-tissue imaging and offers distinct advantages in neuromodulation and tumor delineation due to its spectral window and chemical stability. This is complemented by evidence from studies highlighting its high extinction coefficient and low background, reinforcing its role as a leading amino group reactive fluorescent dye for in vivo applications.

For researchers seeking workflow-oriented guidance, protocol-driven articles provide scenario-based optimization strategies, demonstrating how Cy5.5 NHS ester (non-sulfonated) can be seamlessly integrated into cell viability and cytotoxicity assays, further broadening its utility in molecular biology.

Troubleshooting and Optimization: Maximizing Signal and Reproducibility

While Cy5.5 NHS ester (non-sulfonated) offers robust performance, certain experimental variables require careful attention to achieve optimal results:

• Solubility Challenges: The dye’s low aqueous solubility mandates dissolution in DMSO or DMF; never attempt to dissolve directly in buffer. For large-scale labeling, pre-warm the organic solvent and vortex thoroughly to ensure complete dissolution.
• Buffer Selection: Avoid amine-containing buffers (e.g., Tris, glycine) to prevent quenching of the NHS ester. Instead, use PBS or carbonate buffer, pH 7.4–8.5.
• Labeling Density: Excessive dye:biomolecule ratios can result in self-quenching or impaired biomolecule function. Empirically determine the minimal effective labeling ratio (typically 3–7:1 for proteins) and verify with spectrophotometric quantification.
• Removal of Free Dye: Incomplete purification can lead to high background. Employ size-exclusion chromatography or repeated dialysis to achieve >95% removal of unconjugated dye.
• Photostability and Storage: Labeled conjugates should be stored in the dark at 4°C for short-term use. The solid dye remains stable for 24 months at -20°C, but solutions rapidly degrade and should not be stored overnight.
• Autofluorescence Minimization: The near-infrared excitation/emission profile (cy5 nhs ester) of Cy5.5 NHS ester (non-sulfonated) significantly reduces background from biological samples, but instrument settings (filters, exposure times) should be optimized for maximal signal-to-noise.

For further troubleshooting, resources such as the comprehensive guide on workflow optimization with APExBIO's dye provide detailed protocols and solutions for common labeling pitfalls.

Future Outlook: Expanding the Frontier of Near-Infrared Fluorescent Probes

The advent of non-sulfonated Cy5.5 NHS ester as a protein labeling fluorescent dye and in vivo tumor imaging dye is accelerating innovation in molecular diagnostics, therapeutic monitoring, and translational research. As referenced in the study of ultrasound-triggered piezo-nanoplatforms for epilepsy treatment, the integration of near-infrared fluorescent dyes enables non-invasive, real-time tracking of nanomaterials and therapeutic agents within complex biological environments.

Looking forward, anticipated developments include:

• Multiplexed Imaging: Combining Cy5.5 NHS ester (non-sulfonated) with complementary fluorophores for simultaneous detection of multiple targets in vivo.
• Smart Probes: Engineering responsive probes that alter fluorescence upon specific molecular interactions, further enhancing sensitivity and specificity for tumor or neurological disease imaging.
• Integration with Theranostics: Coupling optical imaging with targeted drug delivery, as demonstrated in nanoplatform-based epilepsy models, to achieve synergistic diagnostic and therapeutic (theranostic) outcomes.
• Customized Labeling Kits: Expanding user-friendly kits for rapid, reproducible labeling of diverse biomolecules, supporting high-throughput screening and clinical translation.

For researchers seeking to translate these advances into their own laboratories, Cy5.5 NHS ester (non-sulfonated) from APExBIO stands as a proven, reliable reagent, underpinned by robust technical support and a growing ecosystem of protocol resources. As near-infrared fluorescence imaging moves to the forefront of molecular biology and biomedical research, the versatility and performance of this NHS ester fluorescent dye will continue to drive innovation, reproducibility, and discovery.